CareDx Surges After Medicare Finalizes Transplant Testing Coverage Policy

CareDx shares rose approximately 18% premarket after Medicare finalized a Local Coverage Determination policy supporting coverage for CareDx's molecular testing in solid organ transplants. The decision is expected to expand access and adoption of the company’s transplant monitoring solutions.

By Sara Sethiya, SA News Editor · Seeking Alpha · July 16, 2026, 13:09 UTC

CareDx Surges After Medicare Finalizes Transplant Testing Coverage Policy

Tickers: $CDNA

Topics: CareDx Medicare Policy Molecular Testing Transplant Diagnostics

Read the full article at Seeking Alpha

More World news

Transamerica Partners with Congruent Solutions to Modernize Retirement Plan Payroll Administration PR Newswire · November 12, 2026, 14:00 UTC
Kindo Raises $57.6 Million Total to Scale Enterprise AI Agent Management Platform PR Newswire · November 12, 2026, 14:00 UTC
Texans Credit Union Introduces Cash Back Checking and Ignite Youth Banking Suite PR Newswire · November 12, 2026, 14:03 UTC
Apple Announces Preorders for Select Smart Home Collection Accessories The Verge · November 12, 2026, 14:00 UTC
SolaREIT Surpasses $8.5 Billion Milestone in Clean Energy Land Financing PR Newswire · November 12, 2026, 14:00 UTC
Avalara Launches Native 1099 E-Filing Integration for Workday Financial Management PR Newswire · November 12, 2026, 14:00 UTC
Rocket Companies Appoints Datadog COO Adam Blitzer to Board of Directors PR Newswire · November 12, 2026, 14:00 UTC
ALKEME Insurance Announces 'ALKEME Bowl' Sponsorship of Arizona vs. Utah College Football Matchup PR Newswire · November 12, 2026, 14:00 UTC
The Pacific Financial Group Partners with Salesforce and Contentful to Enhance Advisor Experience via AI-Driven Personalization PR Newswire · November 12, 2026, 14:01 UTC
Bitdeer Reports 89% Revenue Growth and $7.6 Billion in Contracted AI Revenue Motley Fool · November 12, 2026, 13:57 UTC